Provided by Tiger Trade Technology Pte. Ltd.

Eterna Therapeutics Inc.

2.96
-0.2400-7.50%
Post-market: 2.960.00000.00%18:25 EDT
Volume:35.74K
Turnover:106.99K
Market Cap:4.83M
PE:-0.16
High:3.24
Open:3.13
Low:2.84
Close:3.20
52wk High:71.50
52wk Low:2.84
Shares:1.63M
Float Shares:1.22M
Volume Ratio:1.09
T/O Rate:2.94%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-18.6059
EPS(LYR):-55.8903
ROE:-320.72%
ROA:-105.57%
PB:1.51
PE(LYR):-0.05

Loading ...

Ernexa Therapeutics Appoints Robert J. Spiegel to Board of Directors

Reuters
·
Yesterday

Ernexa Therapeutics CEO Corner Highlights Appointment of DR. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances Erna-101 Toward the Clinic

THOMSON REUTERS
·
Yesterday

Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic

GlobeNewswire
·
Yesterday

Ernexa Therapeutics announces ‘highly encouraging’ results on ERNA-101

TIPRANKS
·
Sep 30

Ernexa Targets Q4 2026 IND Filing for First-in-Human ERNA-101 Trial in Platinum-Resistant Ovarian Cancer

Reuters
·
Sep 30

Ernexa Therapeutics - no Teratoma Formation Observed in Erna-101-Treated Animals Through Six-Month Tumorigenicity Phase

THOMSON REUTERS
·
Sep 30

Ernexa Therapeutics Reports Compelling Erna-101 Safety Results Across Three Critical Ind-Enabling Studies, Advancing Toward Planned Q4 2026 Ind

THOMSON REUTERS
·
Sep 30

Ernexa Therapeutics - Biodistribution Study Shows no Significant Erna-101 Signal in Tumor-Free Animals or Non-Tumor Tissues

THOMSON REUTERS
·
Sep 30

Ernexa Therapeutics - Repeat-Dose Glp Toxicology Study Shows no Erna-101-Related Adverse Findings

THOMSON REUTERS
·
Sep 30

Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND

GlobeNewswire
·
Sep 30

Ernexa Therapeutics selected for Emerging Track at 2026 Cell, Gene meeting

TIPRANKS
·
Sep 29

Ernexa Therapeutics CEO to Present at Cell & Gene Meeting on the Mesa Emerging Track

Reuters
·
Sep 29

Ernexa Therapeutics Director Robert J. Spiegel Files Initial Beneficial Ownership Statement

Reuters
·
Sep 23

Ernexa Therapeutics Appoints Robert J. Spiegel to Board of Directors

Reuters
·
Sep 17

Ernexa Therapeutics - Intends to Broaden Oncology Program and Advance Next-Generation Imsc Candidates

THOMSON REUTERS
·
Sep 15

Ernexa Therapeutics - to Concentrate Near-Term Resources on Erna-101 and Broaden Oncology Strategy

THOMSON REUTERS
·
Sep 15

Ernexa Therapeutics Reports Positive Disease Modifying Erna-201 Preclinical Data, Reinforcing Imsc Platform as Company Accelerates Oncology Strategy and Erna-101 Toward First-in-Human Dosing

THOMSON REUTERS
·
Sep 15

Ernexa Therapeutics - to Advance Erna-101 Toward Ind Submission for Platinum-Resistant Ovarian Cancer

THOMSON REUTERS
·
Sep 15

Ernexa Therapeutics - Clinical Data from Erna-101 Proc Study Expected in Q4 2027

THOMSON REUTERS
·
Sep 15

Ernexa Therapeutics - Pauses Additional Preclinical Development Expenditures on Erna-201

THOMSON REUTERS
·
Sep 15